Loading, please wait ...


News Analytics

osteoporosis consult older woman 2 adobe.
Zoledronate infusion preserves BMD gains after denosumab discontinuation for women with osteoporosis Postmenopausal women with osteoporosis who received a single infusion of zoledronate after 2 to 5 years of denosumab therapy retained more than half of bone mineral density gained before stopping treatment with no increase in vertebral fractures, according to findings published in the Journal of Bone and Mineral Research.

Subject Matter

  • Healthcare 75.68%
    • Hospitals, doctors and medical care 100.00%
  • Science and technology 24.32%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions